Portal de Periódicos da CAPES

Transitional cell carcinoma of the ovary: A matched control study of advanced-stage patients treated with cisplatin-based chemotherapy

1993; Elsevier BV; Volume: 168; Issue: 4 Linguagem: Inglês

10.1016/0002-9378(93)90365-p

1097-6868

David M. Gershenson, Elvio G. Silva, Michele Follen Mitchell, E. Neely Atkiinson, J. Taylor Wharton,

Lymphoma Diagnosis and Treatment

The purpose of this study was to compare patients with advanced-stage transitional cell carcinoma of the ovary with those who had poorly differentiated serous carcinoma for surgical response and survival.Sixty-two patients with transitional cell carcinoma were identified through a retrospective review and were matched with serous carcinoma patients for stage and residual disease. All patients received cisplatin-based chemotherapy. End points selected for analysis were surgical response, progression-free survival time, and survival time. Univariate and multivariate regression analyses were also performed.The surgical complete response rate for patients with transitional cell carcinoma was 37%, compared with 11% for those with serous carcinoma (p < 0.001). The survival time was significantly longer for the patients with transitional cell carcinoma (median 52.3 vs 22.0 months) (p < 0.001). Multivariate analyses strengthened these findings.Transitional cell carcinoma of the ovary is significantly more chemosensitive and associated with a better prognosis than the more common serous carcinoma.